Cellectis S.A. (CLLS) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.4x

Market Cap

$326.27M

MomentumView details →

1D Return

−2.41%

YTD Return

−31.10%

RSI (14)

56.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.4x

Market Cap

$326.27M

RSI (14)

56.1

MomentumView details →

1D Return

−2.41%

YTD Return

−31.10%

SummaryUpdated Jun 1, 2026

Cellectis S.A. (NASDAQ:CLLS) is a French clinical-stage biotechnology company founded in 1999 and headquartered in Paris. The company specializes in developing gene-edited immunotherapy treatments for cancer, particularly focusing on allogeneic CAR-T cell therapies that can be manufactured at scale and used across multiple patients. Cellectis has evolved from its early gene-editing platform origins to become a leading developer of "off-the-shelf" cancer immunotherapies, with multiple clinical programs in various stages of development and a significant strategic partnership with pharmaceutical giant AstraZeneca established in 2024.

Ask drillr about Cellectis S.A. →

ProfitabilityView details →

Gross Margin

74.71%

Net Margin

−115.48%

EBITDA Margin

−98.06%

ROE (TTM)

−159.12%

ROA (TTM)

−24.44%

Asset Turnover

0.20x

GrowthView details →

Revenue YoY

+0.52%

EPS YoY

−12.41%

FCF YoY

−20.41%

Revenue CAGR 3Y

+56.12%

EPS CAGR 3Y

−65.85%

EBITDA YoY

−83.44%

EarningsView details →

EPS (Actual)

−$0.22

EPS Surprise

16.35%

Beats (12Q)

6/12

Next Q EPS Est

−$0.20

Avg Surprise (4Q)

32.20%

Rev Surprise

−37.52%

Capital & dividendView details →

Debt/Equity

2.06x

Current Ratio

1.37x

Quick Ratio

1.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

56.59M

Net Income (TTM)

−65.35M

Op. CF (TTM)

−41.89M

Next earningsNov 13, 2026 →

Latest newsMore news →

Cellectis held its shareholders general meeting on June 25, 2026, where resolutions 1 through 29 were adopted and resolution 30 was rejected.71d ago

The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Cellectis' lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia.87d ago

Similar companies

InflaRx N.V.IFRX Sionna Therapeutics, Inc.SION Pyxis Oncology, Inc.PYXS Vanda Pharmaceuticals Inc.VNDA Upstream Bio, Inc.UPB Sutro Biopharma, Inc.STRO Find similar companies →

Latest newsMore news →

Cellectis held its shareholders general meeting on June 25, 2026, where resolutions 1 through 29 were adopted and resolution 30 was rejected.71d ago The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Cellectis' lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia.87d ago